CareTrust REIT (7XC) Q2 2026 Earnings Report

The call was strongly positive on operational and financial performance: record quarterly investments, robust YTD deployment (~$1.5B), double-digit per-share growth guidance, materially higher normalized FFO/FAD and conservative leverage with ample liquidity. Offsetting items are focused and tactical: competitive pressures and cap rate compression in the SHOP market, modest pricing premium on a large U.K. buy, reliance on unsettled equity forward proceeds and certain guidance assumptions, and multi-year uncertainty around financing receivable purchase options. Overall the strengths (record investment activity, significant FFO/FAD growth, strong balance sheet and operator quality) materially outweigh the select execution and market risks discussed.

CareTrust raised full-year 2026 guidance, now projecting normalized FFO per share of $2.03–$2.06 and normalized FAD per share of $2.01–$2.04 (midpoint implying ~16.2% FFO/share and ~15.1% FAD/share growth vs. 2025) based on a weighted average diluted share count of 233 million; the outlook assumes no new investments/loans/dispositions or debt/equity issuances beyond year‑to‑date activity, 2.5% inflation-based rent escalators on long‑term triple‑net leases, $147 million of loans to be repaid during the year (≈$104 million received to date), and no material change in GBP/USD. The company noted ample liquidity to fund guidance with roughly $1.4 billion available (≈$90 million cash, $605 million revolver availability on a $1.2 billion facility, ≈$671 million unsettled equity forwards and ≈$785.8 million ATM capacity), a net debt to annualized normalized run‑rate EBITDA of 1.0x, fixed charge coverage of 9.9x, and no scheduled debt maturities before 2028.